Literature DB >> 15913495

Clinical trials report. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension.

Kathleen H Berecek, David Calhoun.   

Abstract

Entities:  

Year:  2005        PMID： 15913495     DOI： 10.1007/s11906-005-0011-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  12 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

3.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

5.  Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

Authors:  Stephen Colagiuri; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2002-08       Impact factor: 19.112

6.  Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications.

Authors:  S H Song; P M Brown
Journal:  Diabet Med       Date:  2004-03       Impact factor: 4.359

7.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Authors:  Sharon H Saydah; Judith Fradkin; Catherine C Cowie
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

Authors:  Heinrich Holzgreve; Roumen Nakov; Katrin Beck; Hans Uwe Janka
Journal:  Am J Hypertens       Date:  2003-05       Impact factor: 2.689

10.  Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.

Authors:  A Dornhorst; S H Powell; J Pensky
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.